Neil Sinha
Headshot of Neil Sinha

Neil Sinha

Partner

Email

neil.sinha@aoshearman.com

Phone

+44 203 088 3393

Offices

London

V-CARD
Neil is Private Equity Sector Lead - Europe. He is a market leading sponsor side leveraged finance partner who has a wide range of experience advising private equity firms and their portfolio companies on complex debt financing transactions including cross-border leveraged buy-outs.

Neil has advised a number of top tier private equity funds and financial sponsors including Brookfield Private Equity, CVC Capital Partners, 3i, a global alternative investment management firm, Partners Group, Warburg Pincus, Exponent, ICG Private Equity, Stonepeak, Fiera Capital, Advent, Triton, Providence Equity Partners, Hg Capital and PAI.
 
Neil is recognised as one of the leading sponsor side leveraged finance lawyers in the market and has been profiled as a ‘deals powerhouse’ and ‘a remarkable force in sponsor-side work’ by The Lawyer Hot 100, 2025, a rising star by Legal Business in their article Banking and finance focus: Back to the future, and named in the 40 under 40 Rising Stars in Private Equity (Legal Week 2019). He also led the teams that won Loan Deal of the Year (Ethypharm), High Yield Deal of the Year (Modulaire) at the IFLR Europe Awards, 2022 and Loan Deal of the Year (Action) at the IFLR Awards, 2024. Clients say “Neil is excellent - he is one of the smartest lawyers out there, extremely commercial and well versed on the product level and detail” and “Neil Sinha is one of the best in the business on the leveraged finance side, you are always comfortable he will get you the best terms.” Chambers UK.

Expertise

Industries

Experience

Representative matters

  • Brookfield (Private Equity) on its TLB, SSN and SUN financing to acquire Modulaire.
  • Brookfield (Private Equity) and Greenergy on the refinancing for Greenergy.
  • Brookfield (Private Equity) on its disposal of Greenergy.
  • CVC on its financing for the acquisition of Grupo Monbake.
  • CVC on its financing in connection with the extension of its partnership with Multiversity through a CVC managed continuation fund. 
  • CVC on the financing in respect of its acquisition of UAX. 
  • CVC on its financing in respect of the acquisition of Neolith. 
  • CVC on its financing in respect of the acquisition of Gaming1. 
  • CVC on its financing in respect of the acquisition of Multiversity.
  • CVC on the financing in respect of the acquisition of Corialis.
  • CVC and its portfolio company, Compañía Logística de Hidrocarburos CLH, S.A., on the holdco and target level financing in respect of the acquisition of Exolum Terminals.
  • CVC on the acquisition of Capio Sanidad and the subsequent financing for the transformational acquisition of Quiron.
  • Exponent on the financing for its acquisition of Chanelle Pharma.
  • Exponent on the financing for its acquisition of SHL.
  • Exponent on the financing for its acquisition of Evergreen Garden Care.
  • Exponent and its portfolio company SHL on the refinancing of SHL's existing debt.
  • Exponent and its portfolio company Evergreen on the refinancing of Evergreen’s existing debt.
  • Exponent and Photobox on its financing in respect of the combination of Photobox and Albelli.
  • Exponent on the standalone financings for Moonpig and Photobox following their demerger.
  • Exponent and BBI in respect of the refinancing of BBI.
  • 3i Group plc (3i) on the financing in respect of its investment in WaterWipes.
  • 3i and Action Group on various debt financing transactions for Action including its debut debt raise in the US.
  • ICG (Private Equity) on its financing in respect of the combination of Konecta and Comdata.
  • Partners Group on the financing for its acquisition of FairJourney Biologics.
  • Partners Group on the financing for its acquisition of Cloudflight.
  • Partners Group and CVC on the financing for their potential acquisition of Ceramtec. 
  • PAI on the financing in respect of its acquisition of Ethypharm. 
  • PAI on the refinancing of Ethypharm. 
  • PAI on the financing in respect of its acquisition of Swissport.
  • Providence Equity Partners in respect of the financing for its acquisition of Superstruct.
  • Providence Equity Partners on its portable refinancing of Galileo Global Education.
  • Providence Equity Partners on its financing in respect of Bite.
  • Providence Equity Partners on its financing in respect of the acquisition of Chime Communications.
  • Stonepeak on its financing in respect of the acquisition of euNetworks.
  • Advent on its financing in respect of the acquisition of UNIT4.
  • Carlyle on the financing of Zodiac and the disposal of Zodiac.
  • Hg Capital on its financing in respect of the acquisition of IRIS Software.
  • Galileo Global Education on its refinancing under new ownership and its subsequent debt raises.
  • The debt financing in respect of the acquisition of Mediapro and the subsequent refinancing of Mediapro.

Recognition

“Neil is great. He's very proactive in terms of idea generation as well as shepherding negotiations. This separates the good from the great and he demonstrates great capabilities.”
Legal 500, 2024
“Having Neil on our side when negotiating is extremely important: I trust and rely on him 100%; he really pushes points that matter.”
Chambers UK

Qualifications

Admissions

Admitted as solicitor, England and Wales, 2008
Disclaimer
A&O Shearman was formed on May 1, 2024 by the combination of Shearman & Sterling LLP and Allen & Overy LLP and their respective affiliates (the legacy firms). Any matters referred to above may include matters undertaken by one or more of the legacy firms rather than A&O Shearman.